🟢 Decoy Therapeutics is trading 7% up in after-hours trading after announcing its Ebola-Marburg antiviral program

Decoy Therapeutics is trading 7.10% higher at $3.32 after announcing a pan-filovirus program targeting Ebola and Marburg viruses through the FDA’s Animal Rule pathway.

• A first-generation candidate showed low-micromolar activity against wild-type Ebola Zaire and activity against Marburg in cell-based testing; evidence remains preclinical.
• The company is pursuing potential non-dilutive funding and Priority Review Voucher eligibility. Shares rose 21.09% in regular trading to $3.10 on September 22, extending biotech speculation; volatility remains elevated.